Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported Income from Continuing Operations of 13345000.0 for Q1 2026, up 68.56% on a YoY basis from 7916885.77 in Q1 2025, and down 129.8% sequentially from 44784000.0 in Q4 2025.
Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of Income from Continuing Operations data on file, last reported at 13345000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 68.56% year-over-year to 13345000.0; the trailing twelve-month figure through Mar 2026 stood at 153559000.0 (up 215.79% YoY), and the FY2025 full-year result was 124453000.0, up 3186.63% from the prior year.
- Income from Continuing Operations fell to 13345000.0 in Q1 2026, from 44784000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 117273000.0 in Q3 2025 to a low of 51911000.0 in Q2 2024.
- A 5-year average of 9157411.76 and a median of 2290000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 2366.86% in 2024 and jumped 1735.15% in 2025, its largest moves.
- Tracing LGND's Income from Continuing Operations over 5 years: stood at 14534000.0 in 2022, then soared by 225.14% to 18188000.0 in 2023, then sank by 270.93% to 31088000.0 in 2024, then surged by 244.06% to 44784000.0 in 2025, then plunged by 129.8% to 13345000.0 in 2026.
- Business Quant data shows LGND's Income from Continuing Operations at 13345000.0 in Q1 2026, 44784000.0 in Q4 2025, and 117273000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | -13.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Sep 30, 2024 | -7.17 Mn |
| Jun 30, 2024 | -51.91 Mn |
| Mar 31, 2024 | 86.14 Mn |
| Dec 31, 2023 | 18.19 Mn |
| Sep 30, 2023 | -10.27 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 43.61 Mn |
| Dec 31, 2022 | -14.53 Mn |
| Sep 30, 2022 | 9.65 Mn |
| Jun 30, 2022 | 12.60 Mn |
| Mar 31, 2022 | -12.93 Mn |
| Dec 31, 2021 | 13.80 Mn |
| Sep 30, 2021 | 13.72 Mn |
| Jun 30, 2021 | 30.73 Mn |